You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Eye conditions

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration

  • Technology appraisal guidance
  • Reference number: TA155
  • Published:  27 August 2008
  • Last updated:  20 May 2024
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Consultee and commentator comments on the ACD: Novartis Pharmaceuticals Limited (confidential information removed)

  • Lucentis dose capping pharmacy dispensing form

  • Lucentis dose capping pharmacy claim form

  • The Lucentis dose capping scheme flow diagram

  • Appendix 1 - Dose capping scheme summary proposal to NICE

  • Novartis comment


This page was last updated: 30 March 2010

Back to top